Rep. Thomas H. Kean, Jr. Sells Off Shares of Stryker Corporation (NYSE:SYK)

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on November 20th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.
• Sold $15,001 – $50,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/20/2025.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 9/25/2025.

Stryker Stock Up 0.6%

Shares of SYK stock traded up $2.10 on Friday, hitting $355.21. The stock had a trading volume of 2,755,021 shares, compared to its average volume of 1,578,372. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The business has a 50 day moving average of $365.26 and a 200 day moving average of $377.51. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The stock has a market cap of $135.84 billion, a price-to-earnings ratio of 46.68, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the prior year, the firm posted $2.87 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirabella Financial Services LLP grew its holdings in Stryker by 124.4% during the 3rd quarter. Mirabella Financial Services LLP now owns 10,248 shares of the medical technology company’s stock valued at $3,781,000 after buying an additional 5,681 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Stryker in the third quarter valued at approximately $55,000. Hudson Bay Capital Management LP grew its stake in Stryker by 130.5% during the third quarter. Hudson Bay Capital Management LP now owns 568 shares of the medical technology company’s stock valued at $210,000 after acquiring an additional 2,430 shares in the last quarter. Severin Investments LLC increased its holdings in Stryker by 24.1% during the 3rd quarter. Severin Investments LLC now owns 1,499 shares of the medical technology company’s stock worth $554,000 after acquiring an additional 291 shares during the period. Finally, Swiss Life Asset Management Ltd boosted its holdings in Stryker by 7.0% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 37,984 shares of the medical technology company’s stock valued at $14,042,000 after purchasing an additional 2,486 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SYK. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Barclays boosted their price target on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Citigroup lowered their price objective on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, Redburn Partners set a $420.00 price objective on Stryker in a research note on Thursday, September 18th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $431.84.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.